{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:00Z","timestamp":1791335640909,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00432-020-03457-7","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T09:02:45Z","timestamp":1605862965000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis"],"prefix":"10.1007","volume":"147","author":[{"given":"Roberta","family":"Carosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Banelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Aldo","family":"Canessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dessanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vigani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Poggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Roncella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-4121","authenticated-orcid":false,"given":"Maria Pia","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"3457_CR1","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.4049\/jimmunol.1302044","volume":"191","author":"PK Amancha","year":"2013","unstructured":"Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F (2013) In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol 191:6060\u20136070. https:\/\/doi.org\/10.4049\/jimmunol.1302044","journal-title":"J Immunol"},{"key":"3457_CR2","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.21873\/anticanres.13716","volume":"39","author":"K Ando","year":"2019","unstructured":"Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Rie Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S (2019) Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors. Anticancer Res 39:5195\u20135201. https:\/\/doi.org\/10.21873\/anticanres.13716","journal-title":"Anticancer Res"},{"key":"3457_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","volume":"56","author":"C Blank","year":"2007","unstructured":"Blank C, Mackensen A (2007) Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739\u2013745. https:\/\/doi.org\/10.1007\/s00262-006-0272-1","journal-title":"Cancer Immunol Immunother"},{"key":"3457_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00418-017-1596-y","volume":"148","author":"A Bragoni","year":"2017","unstructured":"Bragoni A, Gambella A, Pigozzi S, Grigolini M, Fiocca R, Mastracci L, Grillo F (2017) Quality control in diagnostic immunohistochemistry: integrated on-slide positive controls. Histochem Cell Biol 148:569\u2013573. https:\/\/doi.org\/10.1007\/s00418-017-1596-y","journal-title":"Histochem Cell Biol"},{"key":"3457_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"key":"3457_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111\u2013122. https:\/\/doi.org\/10.1016\/j.immuni.2007.05.016","journal-title":"Immunity"},{"key":"3457_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1371\/journal.pone.0121071e0121071","volume":"16","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Matinez-Marti A, Martinez P, Felip E (2015) Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 16:10. https:\/\/doi.org\/10.1371\/journal.pone.0121071e0121071","journal-title":"PLoS ONE"},{"key":"3457_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","volume":"87","author":"DB Chapel","year":"2019","unstructured":"Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G (2019) Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol 87:11\u201317. https:\/\/doi.org\/10.1016\/j.humpath.2019.02.001","journal-title":"Hum Pathol"},{"key":"3457_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","volume":"56","author":"Y Chen","year":"2011","unstructured":"Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, Zhang X (2011) Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 56:231\u2013238. https:\/\/doi.org\/10.1016\/j.cyto.2011.06.004","journal-title":"Cytokine"},{"key":"3457_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382\u2013386. https:\/\/doi.org\/10.1038\/s41586-018-0392-8","journal-title":"Nature"},{"key":"3457_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, Topalian SL (2019) Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 7:305. https:\/\/doi.org\/10.1186\/s40425-019-0770-2","journal-title":"J Immunother Cancer"},{"key":"3457_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/cancers12020361","volume":"12","author":"C Chiarucci","year":"2020","unstructured":"Chiarucci C, Cannito S, Daffin\u00e0 MG, Amato G, Giacobini G, Cutaia O, Lofiego MF, Fazio C, Giannarelli D, Danielli R, Di Giacomo AM, Coral S, Calabr\u00f2 L, Maio M, Covre A (2020) Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: correlation with survival. Cancers (Basel) 12:361. https:\/\/doi.org\/10.3390\/cancers12020361","journal-title":"Cancers (Basel)"},{"key":"3457_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Fumiya H, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"3457_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J, Hanley SJB, Watari H (2018) Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol 8:386. https:\/\/doi.org\/10.3389\/fonc.2018.00386","journal-title":"Front Oncol"},{"key":"3457_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","volume":"59","author":"F Finkelmeier","year":"2016","unstructured":"Finkelmeier F, Canli \u00d6, Tal A, Pleli T, Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR, Waidmann O (2016) High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer 59:152\u2013159. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.002","journal-title":"Eur J Cancer"},{"key":"3457_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"17","author":"X Frigola","year":"2011","unstructured":"Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED (2011) Identification of a soluble form of B7\u2013H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 17:1915\u20131923. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0250","journal-title":"Clin Cancer Res"},{"key":"3457_CR17","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","volume":"10","author":"B Ghanim","year":"2020","unstructured":"Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Pl\u00f6nes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C (2020) Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Sci Rep 10:5784. https:\/\/doi.org\/10.1038\/s41598-020-62813-2","journal-title":"Sci Rep"},{"key":"3457_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","volume":"216","author":"B Gong","year":"2019","unstructured":"Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R (2019) Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med 216:982\u20131000. https:\/\/doi.org\/10.1084\/jem.20180870","journal-title":"J Exp Med"},{"key":"3457_CR19","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360\u20133365. https:\/\/doi.org\/10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci USA"},{"key":"3457_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HEK, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567. https:\/\/doi.org\/10.1038\/nature14011","journal-title":"Nature"},{"key":"3457_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","volume":"71","author":"S Inaguma","year":"2018","unstructured":"Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Oko\u0144 K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M (2018) Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Hum Pathol 71:1\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2017.04.032","journal-title":"Hum Pathol"},{"key":"3457_CR22","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sc USA 99:12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sc USA"},{"key":"3457_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z (2019) Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer 18:10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4","journal-title":"Mol Cancer"},{"key":"3457_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"3457_CR25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","volume":"11","author":"S Khanna","year":"2016","unstructured":"Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R (2016) Malignant mesothelioma effusions are infiltrated by CD3 + T cells highly expressing PD-L1 and the PD-L1 + tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol 11:1993\u20132005. https:\/\/doi.org\/10.1016\/j.jtho.2016.07.033","journal-title":"J Thorac Oncol"},{"key":"3457_CR26","doi-asserted-by":"publisher","first-page":"e1310358","DOI":"10.1080\/2162402X.2017.1310358","volume":"6","author":"S Kruger","year":"2017","unstructured":"Kruger S, Legenstein ML, R\u00f6sgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S (2017) Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 6:e1310358. https:\/\/doi.org\/10.1080\/2162402X.2017.1310358","journal-title":"Oncoimmunology"},{"key":"3457_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep25952","author":"SY Lee","year":"2016","unstructured":"Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, Do SK, Kang HG, Lee WK, Seok Y, Lee EB, Jeong JY, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Park JY (2016) PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel\u2013cisplatin chemotherapy. Sci Rep. https:\/\/doi.org\/10.1038\/srep25952","journal-title":"Sci Rep"},{"key":"3457_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED (2014) B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9:1036\u20131040. https:\/\/doi.org\/10.1097\/JTO.0000000000000177","journal-title":"J Thorac Oncol"},{"key":"3457_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041041","author":"J Minnema-Luiting","year":"2018","unstructured":"Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R (2018) Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19041041","journal-title":"Int J Mol Sci"},{"key":"3457_CR30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","volume":"28","author":"CY Mu","year":"2011","unstructured":"Mu CY, Huang JA, Chen Y, Chen C, Zhang XG (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor-infiltrating dendritic cells maturation. Med Oncol 28:682\u2013688. https:\/\/doi.org\/10.1007\/s12032-010-9515-2","journal-title":"Med Oncol"},{"key":"3457_CR31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1183\/09031936.00000811","volume":"38","author":"AW Musk","year":"2011","unstructured":"Musk AW, Olsen N, Alfonso H, Reid H, Mina R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB, de Klerk NH (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38:1420\u20131424. https:\/\/doi.org\/10.1183\/09031936.00000811","journal-title":"Eur Respir J"},{"key":"3457_CR32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50256","author":"KW Ng","year":"2019","unstructured":"Ng KW, Attig J, Young GR, Ottina E, Papamichos SI, Kotsianidis I, Kassiotis G (2019) Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. elife. https:\/\/doi.org\/10.7554\/eLife.50256","journal-title":"elife"},{"key":"3457_CR33","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","volume":"13","author":"T Nomi","year":"2007","unstructured":"Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151\u20132157. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2746","journal-title":"Clin Cancer Res"},{"key":"3457_CR34","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","volume":"11","author":"Y Ohigashi","year":"2005","unstructured":"Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947\u20132953. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1469","journal-title":"Clin Cancer Res"},{"key":"3457_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.11.023","volume":"104","author":"Y Okuma","year":"2017","unstructured":"Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S (2017) High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer 104:1\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.023","journal-title":"Lung Cancer"},{"key":"3457_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"3457_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","volume":"13","author":"NS Patil","year":"2018","unstructured":"Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV (2018) Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol 13:124\u2013133. https:\/\/doi.org\/10.1016\/j.jtho.2017.09.1968","journal-title":"J Thorac Oncol"},{"key":"3457_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41423-019-0245-x","volume":"17","author":"MP Pistillo","year":"2020","unstructured":"Pistillo MP, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, Varesano S, Ven\u00e8 R, Poggi A, Roncella S (2020) IFN-\u03b3 upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1\/PD-L1 blockade. Cell Mol Immunol 17:410\u2013411. https:\/\/doi.org\/10.1038\/s41423-019-0245-x","journal-title":"Cell Mol Immunol"},{"key":"3457_CR39","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella LV, Paterson AM, Sharpe AH, Chandraker A (2012) Role of the PD-1 pathway in the immune response. Am J Transplant 12:2575\u20132587. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04224.x","journal-title":"Am J Transplant"},{"key":"3457_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","volume":"65","author":"S Roncella","year":"2016","unstructured":"Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, Varesano S, Boccardo S, Vigani A, Morabito A, Canessa PA, Giannoni U, Rosenberg I, Valentino A, Fedeli F, Merlo DF, Ceppi M, Riggio S, Romani M, Saverino D, Poggi A, Pistillo MP (2016) CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother 65:909\u2013917. https:\/\/doi.org\/10.1007\/s00262-016-1844-3","journal-title":"Cancer Immunol Immunother"},{"key":"3457_CR41","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"3457_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.trsl.2009.12.001","volume":"155","author":"L Vald\u00e9s","year":"2010","unstructured":"Vald\u00e9s L, San-Jos\u00e9 E, Est\u00e9vez JC, Gonz\u00e1lez-Barcala FJ, Alvarez-Doba\u00f1o JM, Golpe A, Valle JM, Penela P, Vizca\u00edno L, Pose A (2010) Cholesterol in pleural exudates depends mainly on increased capillary permeability. Transl Res 155:178\u2013184. https:\/\/doi.org\/10.1016\/j.trsl.2009.12.001","journal-title":"Transl Res"},{"key":"3457_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022","author":"Y Wu","year":"2019","unstructured":"Wu Y, Chen W, Xu ZP, Gu W (2019) PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02022","journal-title":"Front Immunol"},{"key":"3457_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3978\/j.issn.1000-9604.2014.02.08","volume":"26","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H, Wang X, Hu Y, Ji J (2014) Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 26:104\u2013111. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2014.02.08","journal-title":"Chin J Cancer Res"},{"key":"3457_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS (2017) Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res 5:480\u2013492. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0329","journal-title":"Cancer Immunol Res"},{"key":"3457_CR46","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8:97671\u201397682. https:\/\/doi.org\/10.18632\/oncotarget.18311","journal-title":"Oncotarget"},{"key":"3457_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L (2008) Inhibitory B7-family molecule in the tumour microenvironment. Nat Rev Immunol 8:467\u2013477. https:\/\/doi.org\/10.1038\/nri2326","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03457-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03457-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03457-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T10:24:07Z","timestamp":1611138247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03457-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3457"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03457-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee of the Liguria Region (P.R. 207REG2014) after obtaining written informed consent from all participating patients. All procedures performed in this study were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}